Literature DB >> 16888192

VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts.

Y Juarranz1, I Gutiérrez-Cañas, A Arranz, C Martínez, C Abad, J Leceta, J L Pablos, R P Gomariz.   

Abstract

It has been demonstrated that VIP produces beneficial effects both in a murine model of rheumatoid arthritis and in human rheumatoid synovial fibroblasts through the modulation of proinflammatory mediators. Toll-like receptors (TLRs) play a key role in the immediate recognition of microbial surface components by immune cells prior to the development of adaptative microbe-specific immune responses. In this study, we demonstrate that VIP decreases lipopolysaccharide (LPS) and TNF-alpha-induced expression of TLR4 and its correlation with the production of CCL2 and CXCL8 chemokines in human synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Our results add a new step for the use of VIP, as a promising candidate, for the treatment of rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16888192     DOI： 10.1196/annals.1317.045

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  8 in total

1.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

Review 2.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

3.  VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction.

Authors:  Mar Carrión; Yasmina Juarranz; Iria V Seoane; Carmen Martínez; Isidoro González-Álvaro; José Luis Pablos; Irene Gutiérrez-Cañas; Rosa P Gomariz
Journal:  J Mol Neurosci       Date:  2013-11-20       Impact factor: 3.444

Review 4.  TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.

Authors:  Rodolfo Gómez; Amanda Villalvilla; Raquel Largo; Oreste Gualillo; Gabriel Herrero-Beaumont
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

5.  Ameliorative effects of PACAP against cartilage degeneration. Morphological, immunohistochemical and biochemical evidence from in vivo and in vitro models of rat osteoarthritis.

Authors:  Salvatore Giunta; Alessandro Castorina; Rubina Marzagalli; Marta Anna Szychlinska; Karin Pichler; Ali Mobasheri; Giuseppe Musumeci
Journal:  Int J Mol Sci       Date:  2015-03-13       Impact factor: 5.923

Review 6.  Role of vasoactive intestinal peptide in osteoarthritis.

Authors:  Wei Jiang; Hua Wang; Yu-Sheng Li; Wei Luo
Journal:  J Biomed Sci       Date:  2016-08-23       Impact factor: 8.410

Review 7.  Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review.

Authors:  Daisuke Tateiwa; Hideki Yoshikawa; Takashi Kaito
Journal:  Cells       Date:  2019-08-02       Impact factor: 6.600

Review 8.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

Authors:  Carmen Martínez; Yasmina Juarranz; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; David Castro; Amalia Lamana; Mario Mellado; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.